Disease · MONDO_0005530

opiate dependence

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. opiate dependence. Diseases, record MONDO_0005530. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005530

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: opiate dependence; Open Targets
Open Targets ID: MONDO_0005530; Open Targets
Other names: Opioid-Related Disorders, opiate abuse, opiate addiction, opioid abuse, opioid dependence, opioid type dependence; Open Targets
Disease Ontology: DOID:2559; Disease Ontology
MeSH: D009293; MeSH
Highest stage of its drugs: Approval, for 9 of its 64 drugs, from DailyMed, EMA Human Drugs and TTD; Open Targets

Drugs64

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BUPRENORPHINE	CHEMBL511142	Small molecule	Approval	DailyMed, EMA Human Drugs and TTD	120	109	109	Drugs and targets
NALOXONE	CHEMBL80	Small molecule	Approval	EMA Human Drugs and TTD	35	31	31	Drugs and targets
LOFEXIDINE	CHEMBL17860	Small molecule	Approval	TTD	6	5	5	Drugs and targets
LEVOMETHADYL ACETATE	CHEMBL1514	Small molecule	Approval	TTD	3	1	1	Drugs and targets
METHADONE HYDROCHLORIDE	CHEMBL1200825	Small molecule	Approval	DailyMed	3	0	0	Drugs and targets
METHADYL ACETATE	CHEMBL170179	Small molecule	Approval	TTD	1	0	0	Drugs and targets
METHYLNALTREXONE BROMIDE	CHEMBL1201770	Small molecule	Approval	EMA Human Drugs	1	0	0	Drugs and targets
NALMEFENE	CHEMBL982	Small molecule	Approval	TTD	1	0	0	Drugs and targets
NALOXEGOL	CHEMBL2219418	Small molecule	Approval	EMA Human Drugs	1	0	0	Drugs and targets
NALTREXONE	CHEMBL19019	Small molecule	Phase 3	ClinicalTrials.gov	38	38	38	Drugs and targets

1 to 10 of 64

See all 64 drugs

Targets67

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
OPRM1	Mu-type opioid receptor	17	Mu opioid receptor agonist; Mu opioid receptor antagonist; Opioid receptors; mu/kappa/delta antagonist	Approval	https://conductscience.org/library/genes/4988	Drugs and targets
OPRK1	Kappa-type opioid receptor	5	Kappa opioid receptor agonist; Kappa opioid receptor partial agonist; Opioid receptors; mu/kappa/delta antagonist	Approval	https://conductscience.org/library/genes/4986	Drugs and targets
ADRA2A	Adrenergic receptor alpha-2	4	Adrenergic receptor alpha-2 agonist; Adrenergic receptor alpha-2 antagonist	Approval	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor alpha-2	4	Adrenergic receptor alpha-2 agonist; Adrenergic receptor alpha-2 antagonist	Approval	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor alpha-2	4	Adrenergic receptor alpha-2 agonist; Adrenergic receptor alpha-2 antagonist	Approval	https://conductscience.org/library/genes/152	Drugs and targets
HTR2A	5-hydroxytryptamine receptor 2A	4	Serotonin 2a (5-HT2a) receptor antagonist	Phase 3	https://conductscience.org/library/genes/3356	Drugs and targets
SLC6A2	Sodium-dependent noradrenaline transporter	4	Norepinephrine transporter inhibitor; Norepinephrine transporter releasing agent	Phase 2	https://conductscience.org/library/genes/6530	Drugs and targets
DRD2	D(2) dopamine receptor	3	Dopamine D2 receptor antagonist	Phase 3	https://conductscience.org/library/genes/1813	Drugs and targets
GRIN2A	Glutamate [NMDA] receptor	3	Glutamate [NMDA] receptor negative allosteric modulator; Glutamate [NMDA] receptor subunit epsilon 1 antagonist	Phase 3	https://conductscience.org/library/genes/2903	Drugs and targets
HTR2C	5-hydroxytryptamine receptor 2C	3	Serotonin 2c (5-HT2c) receptor antagonist	Phase 3	https://conductscience.org/library/genes/3358	Drugs and targets

1 to 10 of 67

See all 67 targets

Trials199

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01908842	Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults	Phase 3	759	2015-05-22	Opioid Dependence, on Agonist Therapy	BUPRENORPHINE	Its record names the disease	ClinicalTrials.gov
NCT01903005	Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence	Phase 4	668	2015-10-28	Opioid Dependence, on Agonist Therapy	BUPRENORPHINE	Its record names the disease	ClinicalTrials.gov
NCT01218997	ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®)	Phase 3	436	2010-12-13	Alcoholism	NALTREXONE	Its record names the disease	ClinicalTrials.gov
NCT00723749	Treatment of Opioid Dependent Patients With Suboxone: Acceptability & Safety Data From Real Life Scenario (Study P05603)		384	2012-04-05	Opioid-Related Disorders, Opiate Dependence, Drug Abuse	BUPRENORPHINE, NALOXONE	Its record names the disease	ClinicalTrials.gov
NCT00640835	Safety and Tolerability of Buprenorphine/Naloxone Film Strips	Phase 2	382	2010-10-26	Opioid-Related Disorders	BUPRENORPHINE, NALOXONE	Its record names the disease	ClinicalTrials.gov
NCT00913770	Models of Screening, Brief Intervention With a Facilitated Referral to Treatment (SBIRT) for Opioid Patients in the Emergency Department	Not applicable	329	2015-05-28	Opiate Addiction	BUPRENORPHINE	Its record names the disease	ClinicalTrials.gov
NCT03089983	Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings	Not applicable	316	2026-02-09	Opioid Dependence, Addiction, HIV/AIDS, Tuberculosis, Hepatitis	ISONIAZID, METHADONE, RIFAPENTINE	Its record names the disease	ClinicalTrials.gov
NCT01848054	Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence	Phase 3	313	2015-06-24	Opioid-Related Disorders, Opiate Dependence	BUPRENORPHINE, NALOXONE	Its record names the disease	ClinicalTrials.gov
NCT01402492	Cocaine Use Reduction With Buprenorphine	Phase 2/3	302	2021-10-29	Cocaine Dependence	BUPRENORPHINE, NALTREXONE	Its record names the disease	ClinicalTrials.gov
NCT00678418	ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence	Phase 3	250	2011-01-21	Opiate Dependence	NALTREXONE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 199

See all 199 trials

Comparisons in its trials82

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
BNX Tablets, Then OL BNX Tablets, Then BNX Film vs Buprenorphine, Then OL BNX Film, Then BNX Tablets: serious adverse events	3 of 383	1 of 375	758	NCT01908842	Trial comparisons
Medisorb Naltrexone 380 mg (VIVITROL) vs Oral Naltrexone 50 mg: Number of Subjects Reporting at Least 1 Treatment-emergent Adverse Event (TEAE) While on Study	336 of 371	53 of 65	436	NCT01218997	Trial comparisons
Medisorb Naltrexone 380 mg (VIVITROL) vs Oral Naltrexone 50 mg: serious adverse events	49 of 371	5 of 65	436	NCT01218997	Trial comparisons
Buprenorphine/Naloxone Film Strip Administered Sublingually vs Buprenorphine/Naloxone Film Strip Administered Buccally: Number of Subjects With Treatment-emergent Adverse Events Associated With the Oral Cavity.	11 of 194	16 of 188	382	NCT00640835	Trial comparisons
Buprenorphine/Naloxone Film Strip Administered Sublingually vs Buprenorphine/Naloxone Film Strip Administered Buccally: serious adverse events	4 of 194	2 of 188	382	NCT00640835	Trial comparisons
Standard Isoniazid (INH) for 26 Weeks vs Short-course Isoniazid + Rifapentine (INH + RIF) for 12 Weeks: Discontinuation Due to Experiencing an Adverse Event	10 of 156	1 of 156	312	NCT03089983	Trial comparisons
Standard Isoniazid (INH) for 26 Weeks vs Short-course Isoniazid + Rifapentine (INH + RIF) for 12 Weks: deaths from any cause	0 of 156	0 of 156	312	NCT03089983	Trial comparisons
Standard Isoniazid (INH) for 26 Weeks vs Short-course Isoniazid + Rifapentine (INH + RIF) for 12 Weks: serious adverse events	0 of 156	0 of 156	312	NCT03089983	Trial comparisons
BNX Sublingual Tablets Induction vs Buprenorphine Induction: Retention in Treatment in the Full Analysis Population	132 of 155	147 of 155	310	NCT01848054	Trial comparisons
BNX Sublingual Tablets Induction vs Buprenorphine Induction: serious adverse events	1 of 155	2 of 155	310	NCT01848054	Trial comparisons

1 to 10 of 82

See all 82 comparisons in its trials

Papers from its trials131

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41042438	RESULT	1	PubMed
38337458	RESULT	1	PubMed
38285446	RESULT	1	PubMed
37404968	RESULT	1	PubMed
37302533	RESULT	1	PubMed
35386013	RESULT	1	PubMed
35356723	RESULT	1	PubMed
32885244	RESULT	1	PubMed
32371500	RESULT	1	PubMed
31786934	RESULT	1	PubMed

1 to 10 of 131

See all 131 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005530

GET https://conductscience.org/api/diseases/v1/MONDO_0005530/drugs?page=2

API reference For AI assistants